Morini G, Grandi D, Stark H, Schunack W
Institute of Pharmacology, University of Parma, 43100 Parma, Italy.
Br J Pharmacol. 2000 Apr;129(8):1597-600. doi: 10.1038/sj.bjp.0703249.
(R)-alpha-methylhistamine, a selective agonist of histamine H(3) receptors, is capable of protecting the gastric mucosa against differently acting damaging agents. The objective of the present study was to determine whether H(3) receptors mediate its protective action in the rat. Gastric mucosal lesions were induced intragastrically (i.g.) by 0.6 N HCl, 1 ml rat(-1). (R)-alpha-methylhistamine, 100 mg kg(-1) i.g., substantially reduced the severity of macroscopically and histologically assessed damage caused by concentrated acid. Prior treatment with highly selective H(3)-receptor antagonists, ciproxifan (0.3, 1 and 3 mg kg(-1) i.g.) and clobenpropit (3, 10 and 30 mg kg(-1) i.g.), dose-dependently inhibited the protection exerted by (R)-alpha-methylhistamine up to a complete reversal. When given alone at high doses, both antagonists tended to worsen the HCl-induced histologic damage. During basal conditions, (R)-alpha-methylhistamine, 100 mg kg(-1) i. g., caused a significant increase in titratable acidity of the gastric juice. Prior treatment with ciproxifan (3 mg kg(-1) i.g.) and clobenpropit (30 mg kg(-1) i.g.) did not alter the secretory response to (R)-alpha-methylhistamine. Clobenpropit alone, but not ciproxifan, increased the volume of gastric juice, and both compounds alone had no effect on titratable acid. Present findings support evidence that H(3) receptors are actively involved in the maintenance of gastric mucosal integrity, with no apparent role in the regulation of basal gastric acid secretion.
(R)-α-甲基组胺是组胺H3受体的选择性激动剂,能够保护胃黏膜免受不同作用的损伤因子侵害。本研究的目的是确定H3受体是否介导其在大鼠中的保护作用。通过向大鼠胃内注射1ml 0.6N盐酸诱导胃黏膜损伤。胃内注射100mg/kg体重的(R)-α-甲基组胺可显著减轻高浓度酸引起的宏观和组织学评估的损伤严重程度。预先用高选择性H3受体拮抗剂西普瑞凡(0.3、1和3mg/kg体重,胃内注射)和氯苯丙哌嗪(3、10和30mg/kg体重,胃内注射)进行处理,剂量依赖性地抑制(R)-α-甲基组胺的保护作用,直至完全逆转。当高剂量单独给药时,两种拮抗剂都倾向于加重盐酸诱导的组织学损伤。在基础条件下,胃内注射100mg/kg体重的(R)-α-甲基组胺会导致胃液可滴定酸度显著增加。预先用西普瑞凡(3mg/kg体重,胃内注射)和氯苯丙哌嗪(30mg/kg体重,胃内注射)处理不会改变对(R)-α-甲基组胺的分泌反应。单独使用氯苯丙哌嗪会增加胃液量,但西普瑞凡不会,且两种化合物单独使用对可滴定酸均无影响。目前的研究结果支持以下证据:H3受体积极参与维持胃黏膜完整性,而在基础胃酸分泌调节中无明显作用。